Cagrilintide – 10mg

Cagrilintide is a long acting synthetic analogue of amylin, a 37 amino acid peptide co secreted with insulin by pancreatic beta cells in response to nutrient intake. Engineered with structural modifications that extend its half-life from amylin’s native minutes to approximately 7 days, making it one of the longest acting amylin analogues in current research. iLab Pharma’s formulation supplies 10mg as a lyophilized vial, preserving peptide structural integrity and potency across storage conditions until reconstitution, important for a structurally modified amylin analogue where maintaining the engineered peptide conformation is critical to receptor binding activity.

Cagrilintide’s mechanism of action operates through amylin receptor activation, a receptor complex comprising the calcitonin receptor combined with receptor activity modifying proteins (RAMPs) producing a distinct receptor pharmacology from GLP-1, GIP, and glucagon receptor pathways. Amylin receptor activation drives complementary satiety signaling through central nervous system area postrema and nucleus tractus solitarius pathways, gastric emptying regulation, and glucagon suppression through mechanisms operating independently from incretin receptor pathways. This receptor independence is the defining research characteristic that positions Cagrilintide as a uniquely valuable standalone research compound and explains its combination with Trz in CSD’s Cagri-TRZ blend. The two compounds’ completely non overlapping receptor systems producing additive rather than redundant metabolic effects when co administered.

Cagrilintide’s long acting structural modifications including fatty acid chain conjugation and amino acid substitutions that improve metabolic stability. Produce a weekly administration profile consistent with its development program by Novo Nordisk, where it has progressed through clinical trials examining obesity and type 2 diabetes endpoints both as a standalone compound and in combination with semaglutide. This clinical development trajectory contributes a growing human research literature base that distinguishes Cagrilintide from most amylin analogue research compounds and positions it as one of the most clinically relevant amylin receptor agonists currently available for research sourcing. CSD stocks Cagrilintide both as this standalone 10mg vial and as a component of the iLab Pharma Cagri-TRZ blend, giving researchers the flexibility to examine amylin receptor activity in isolation or in combination with incretin receptor co activation from a single verified Canadian supplier.

iLab Pharma formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and iLab Pharma’s Cagrilintide meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside Cagri-TRZ blend and GLP-1 agonist compounds in comparative amylin and incretin receptor pathway studies. Browse CSD’s full peptide range for complete sourcing.